203 related articles for article (PubMed ID: 17962140)
1. Cardiorenal anemia syndrome in chronic kidney disease.
Tarng DC
J Chin Med Assoc; 2007 Oct; 70(10):424-9. PubMed ID: 17962140
[TBL] [Abstract][Full Text] [Related]
2. Clinical considerations and practical recommendations for the primary care practitioner in the management of anemia of chronic kidney disease.
Basile JN
South Med J; 2007 Dec; 100(12):1200-7. PubMed ID: 18090962
[TBL] [Abstract][Full Text] [Related]
3. Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease.
Mix TC; Brenner RM; Cooper ME; de Zeeuw D; Ivanovich P; Levey AS; McGill JB; McMurray JJ; Parfrey PS; Parving HH; Pereira BJ; Remuzzi G; Singh AK; Solomon SD; Stehman-Breen C; Toto RD; Pfeffer MA
Am Heart J; 2005 Mar; 149(3):408-13. PubMed ID: 15864229
[TBL] [Abstract][Full Text] [Related]
4. Methoxy Polyethylene Glycol-Epoetin Beta as a Novel Erythropoiesis Stimulating Agent with Possible Nephroprotective and Cardiovascular Protective Effects in Non-Dialysis Chronic Kidney Disease Patients.
Piotr B; Mariusz S; Jacek R
Curr Pharm Biotechnol; 2017; 18(4):303-308. PubMed ID: 28137221
[TBL] [Abstract][Full Text] [Related]
5. [Regarding the optimal hemoglobin target range in renal anemia].
Maurin N
Med Klin (Munich); 2008 Sep; 103(9):633-7. PubMed ID: 18813886
[TBL] [Abstract][Full Text] [Related]
6. Are there implications from the Trial to Reduce Cardiovascular Events with Aranesp Therapy study for anemia management in dialysis patients?
Berns JS
Curr Opin Nephrol Hypertens; 2010 Nov; 19(6):567-72. PubMed ID: 20601876
[TBL] [Abstract][Full Text] [Related]
7. [TREAT or not to treat: anemia in type 2 diabetes and chronic kidney disease at stages 3 and 4].
Choukroun G; Renou M; Lecaque C; Jauréguy M
Nephrol Ther; 2011 Feb; 7(1):2-9. PubMed ID: 21216683
[TBL] [Abstract][Full Text] [Related]
8. [Anemia in chronic kidney disease and its cardiovascular implications].
Cases A; Coll E; Collado S
Med Clin (Barc); 2009 May; 132 Suppl 1():38-42. PubMed ID: 19460479
[TBL] [Abstract][Full Text] [Related]
9. Anemia management in chronic kidney disease.
Gillespie BS; Inrig JK; Szczech LA
Hemodial Int; 2007 Jan; 11(1):15-20. PubMed ID: 17257350
[TBL] [Abstract][Full Text] [Related]
10. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
11. Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 Months before the Initiation of Hemodialysis: Comparison of Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator.
Yoshida T; Hayashi M
Keio J Med; 2017 Sep; 66(3):44-50. PubMed ID: 27990008
[TBL] [Abstract][Full Text] [Related]
12. The deadly triangle of anemia, renal insufficiency, and cardiovascular disease: implications for prognosis and treatment.
McCullough PA; Lepor NE
Rev Cardiovasc Med; 2005; 6(1):1-10. PubMed ID: 15741920
[TBL] [Abstract][Full Text] [Related]
13. Anemia as a risk factor for chronic kidney disease.
Iseki K; Kohagura K
Kidney Int Suppl; 2007 Nov; (107):S4-9. PubMed ID: 17943141
[TBL] [Abstract][Full Text] [Related]
14. Anemia, chronic renal disease and congestive heart failure--the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists.
Silverberg DS; Wexler D; Iaina A; Steinbruch S; Wollman Y; Schwartz D
Int Urol Nephrol; 2006; 38(2):295-310. PubMed ID: 16868702
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of anemia in chronic kidney disease--position statement of the Croatian Society for Nephrology, Dialysis and Transplantation and review of the KDIGO and ERPB guidelines].
Rački S; Bašić-Jukić N; Kes P; Ljutić D; Lovčić V; Prkačin I; Radić J; Vujičić B; Bubić I; Jakić M; Belavić Ž; Sefer S; Pehai M; Klarić D; Gulin M;
Acta Med Croatica; 2014 Apr; 68(2):215-21. PubMed ID: 26012163
[TBL] [Abstract][Full Text] [Related]
16. Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies.
Wish JB; Coyne DW
Mayo Clin Proc; 2007 Nov; 82(11):1371-80. PubMed ID: 17976358
[TBL] [Abstract][Full Text] [Related]
17. [Anemia and cardiovascular risk in the chronic kidney disease population--which hemoglobin target should be reached?].
Krzesinski JM; Dubois B
Rev Med Liege; 2007; 62(5-6):366-70. PubMed ID: 17725208
[TBL] [Abstract][Full Text] [Related]
18. [Current management of renal anemia in patients with chronic kidney disease at the predialysis stage].
Kuriyama S; Otsuka Y; Uetake D; Shirai I; Hosoya T
Nihon Jinzo Gakkai Shi; 2007; 49(5):505-10. PubMed ID: 17695813
[TBL] [Abstract][Full Text] [Related]
19. Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT).
McMurray JJ; Uno H; Jarolim P; Desai AS; de Zeeuw D; Eckardt KU; Ivanovich P; Levey AS; Lewis EF; McGill JB; Parfrey P; Parving HH; Toto RM; Solomon SD; Pfeffer MA
Am Heart J; 2011 Oct; 162(4):748-755.e3. PubMed ID: 21982669
[TBL] [Abstract][Full Text] [Related]
20. Anemia and cardiovascular risk: the lesson of the CREATE Trial.
Locatelli F; Del Vecchio L; Pozzoni P
J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S262-6. PubMed ID: 17130272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
